Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status.

CONCLUSIONS: CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for advanced BC patients previously classified as unfit for current treatment options.
PMID: 30242024 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 21, 2018 Category: Cancer & Oncology Authors: Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, Garcia-Escudero R, Lorz C, Gomez-Rodriguez MJ, De Velasco G, Otero Blas I, Villacampa F, Guerrero-Ramos Tags: Clin Cancer Res Source Type: research